Chlamydia pneumoniae infection is associated with atherosclerotic heart and vessel disease, but a causal relationship between this pathogen and the disease process has not been established. Recently, it was reported that C. pneumoniae induces human macrophage foam cell formation, a key event in early atheroma development, suggesting a role for the organism in atherogenesis. This study further examines C. pneumoniae-induced foam cell formation in the murine macrophage cell line RAW-264.7. Infected RAW cells accumulated cholesteryl esters when cultured in the presence of low-density lipoprotein in a manner similar to that described for human macrophages. Exposure of C. pneumoniae elementary bodies to periodate, but not elevated temperatures, inhibited cholesteryl ester accumulation, suggesting a role for chlamydial lipopolysaccharide (cLPS) in macrophage foam cell formation. Purified cLPS was found to be sufficient to induce cholesteryl ester accumulation and foam cell formation. Furthermore, the LPS antagonist lipid X inhibited C. pneumoniae and cLPS-induced lipid uptake. These data indicate that cLPS is a C. pneumoniae component that induces macrophage foam cell formation and suggest that infected macrophages chronically exposed to cLPS may accumulate excess cholesterol to contribute to atheroma development.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC108631 | PMC |
http://dx.doi.org/10.1128/IAI.66.11.5067-5072.1998 | DOI Listing |
Sci Rep
January 2025
School of Civil Engineering, Central South University, Changsha, 410083, China.
This study investigates the deposition of tantalum (Ta) coatings on carbon foams using the chemical vapor deposition (CVD) method to enhance their compressive strength. Two types of open-cell carbon foams, CF-1 and CF-2, with different strut diameters, were examined. The morphology and uniformity of the coatings were characterized, and the effect of coating thickness on the compressive strength of the foams was systematically analyzed.
View Article and Find Full Text PDFCardiovasc Toxicol
January 2025
Department of Cardiovascular Medicine, The Affiliated Panyu Central Hospital of Guangzhou Medical University (Cardiovascular Diseases Research Institute of Panyu District), No. 8, Fuyu East Road, Qiaonan Street, Panyu District, Guangzhou, 511400, China.
The mortality rate of cardiovascular and cerebrovascular diseases ranks first among all causes. This study elucidated the role and potential mechanism of the NLRC5 gene in atherosclerosis (AS). We enrolled patients (number = 30) diagnosed with AS and healthy volunteers (number = 30) as controls from our hospital.
View Article and Find Full Text PDFSoft Matter
January 2025
James Franck Institute and Department of Physics, The University of Chicago, Chicago, Illinois 60637, USA.
We measure the response of open-cell polyurethane foams filled with a dense suspension of fumed silica particles in polyethylene glycol at compression speeds spanning several orders of magnitude. The gradual compressive stress increase of the composite material indicates the existence of shear rate gradients in the interstitial suspension caused by wide distributions in pore sizes in the disordered foam network. The energy dissipated during compression scales with an effective internal shear rate, allowing for the collapse of three data sets for different pore-size foams.
View Article and Find Full Text PDFAm J Chin Med
January 2025
Department of Pathophysiology.
The accumulation of aging cells significantly contributes to chronic inflammatory diseases such as atherosclerosis. Human carotid artery single-cell sequencing has shown that large numbers of aging foam cells are present in the plaques of human patients. Berberine (BBR) has been shown to inhibit cell senescence, however, the mechanisms involved in its treatment of atherosclerotic senescence have not yet been determined.
View Article and Find Full Text PDFJ Appl Toxicol
January 2025
School of Pharmaceutical Sciences, Nanjing Tech University, Nanjing, China.
Sulcardine sulfate (Sul) is a novel antiarrhythmic agent blocking multiple channels and exhibits unique pharmacological properties such as lower APD-dependent prolongation and reduced arrhythmia risk. Sul is currently in Phase III clinical trials, yet studies on its long-term toxicological profile and potential target organs remain unexplored. This study investigated the related toxicity of Sul in Sprague Dawley (SD) rats through repeated oral administration for 26 weeks, followed by a 4-week recovery period.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!